...
首页> 外文期刊>Die Pharmazie >Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media
【24h】

Dissolution properties of co-amorphous drug-amino acid formulations in buffer and biorelevant media

机译:共非晶药物氨基酸制剂在缓冲液和生物相关介质中的溶解特性

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Co-amorphous formulations, particularly binary drug-amino acid mixtures, have been shown to provide enhanced dissolution for poorly-soluble drugs and improved physical stability of the amorphous state. However, to date the dissolution properties (mainly intrinsic dissolution rate) of the co-amorphous formulations have been tested only in buffers and their supersaturation ability remain unexplored. Consequently, dissolution studies in simulated intestinal fluids need to be conducted in order to better evaluate the potential of these systems in increasing the oral bioavailability of biopharmaceutics classification system class II drugs. In this study, solubility and dissolution properties of the co-amorphous simvastatin-lysine, gibenclamide-serine, glibenclamide-threonine and glibenclamide-serine-threonine were studied in phosphate buffer pH 7.2 and biorelevant media (fasted and fed state simulated intestinal fluids (FaSSIF and FeSSIF, respectively)). The co-amorphous formulations were found to provide a long-lasting supersaturation and improve the dissolution of the drugs compared to the crystalline and amorphous drugs alone in buffer. Similar improvement, but in lesser extent, was observed in biorelevant media suggesting that a dissolution advantage observed in aqueous buffers may overestimate the advantage in vivo. However, the results show that, in addition to stability advantage shown earlier, co-amorphous drug-amino acid formulations provide dissolution advantage over crystalline drugs in both aqueous and biorelevant conditions.
机译:已显示共非晶制剂,特别是二元药物-氨基酸混合物,可为难溶性药物提供增强的溶解性,并改善非晶态的物理稳定性。然而,迄今为止,仅在缓冲液中测试了无定形制剂的溶出特性(主要是固有溶出速率),其过饱和能力尚未得到开发。因此,需要进行在模拟肠液中的溶出度研究,以便更好地评估这些系统在提高生物药物分类系统II类药物的口服生物利用度方面的潜力。在这项研究中,研究了非晶态辛伐他汀-赖氨酸,吉本苯胺-丝氨酸,格列本脲-苏氨酸和格列本脲-丝氨酸-苏氨酸在磷酸盐缓冲液pH 7.2和生物相关介质(禁食和进食模拟肠液(FaSSIF和FeSSIF))。与仅在缓冲液中的结晶药物和无定形药物相比,发现该无定形制剂可提供持久的过饱和并改善药物的溶出度。在生物相关介质中观察到类似的改善,但程度较小,表明在水性缓冲液中观察到的溶出度优势可能高估了体内的优势。然而,结果表明,除了较早显示的稳定性优点外,在水性和生物相关条件下,共结晶药物-氨基酸制剂相对于结晶药物均具有溶解优势。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号